Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT vs CRT in high-risk locally advanced rectal cancer (TNT-2)
NCT03177382Phase 3Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2017
- Primary completion
- May 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine and oxaliplatin in rectal cancer (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Disease-Free Survival at 3 years. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03177382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03177382.